Results 101 to 110 of about 430,765 (317)
The mutational status of p53 can influence its recognition by human T-cells
OncoImmunology, 2017 p53 was reported to be an attractive immunotherapy target because it is mutated in approximately half of human cancers, resulting in its inactivation and often accumulation in tumor cells.
Katerina Shamalov +3 more
doaj +1 more source
The Acetyltransferase p300/CBP-Associated Factor Is a p53 Target Gene in Breast Tumor Cells
Neoplasia: An International Journal for Oncology Research, 2004 p300/CBP-associated factor (PCAF) is a coactivator of the tumor suppressor, p53. PCAF participates in p53's transactivation of target genes through acetylation of both bound p53 and histones within p53 target promoters.
George S. Watts +6 more
doaj +1 more source
Molecular Oncology, EarlyView.The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant +7 more
wiley +1 more source
Presença da proteína p53 em carcinomas epidermóides de cabeça e pescoço: correlação histopatológica e implicação prognóstica em 31 casos [PDF]
, 2002 Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-Graduação em Ciências MédicasIntrodução: A mutação do gene p53 é a alteração genética mais freqüentemente detectada em tumores de cabeça ...
Stoeberl, Luís Carlos
core
FEBS Open Bio, EarlyView.Chemotherapy side effects significantly impact cancer survivors' quality of life. Using protein levels in blood samples from breast cancer patients before and after 12 weeks of taxane treatment, we detected treatment‐dependent changes in calcium signaling and aging pathways associated with cancer recurrence.
Saira Munshani +6 more
wiley +1 more source
FEBS Open Bio, EarlyView.UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová +2 more
wiley +1 more source
Phenotype specific analyses reveal distinct regulatory mechanism for chronically activated p53.
PLoS Genetics, 2015 The downstream functions of the DNA binding tumor suppressor p53 vary depending on the cellular context, and persistent p53 activation has recently been implicated in tumor suppression and senescence.
Kristina Kirschner +15 more
doaj +1 more source
Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells
FEBS Open Bio, EarlyView.Loss of AMBRA1 in melanoma cells activates multiple oncogenic pathways associated with tumor progression. Transcriptomic and protein network analyses revealed that AMBRA1 depletion enhances MAPK/ERK signaling, angiogenesis, TGF‐β/EMT signaling, and Wnt/axon guidance pathways.
Milad Ibrahim +4 more
wiley +1 more source
Models incorporating chromatin modification data identify functionally important p53 binding sites [PDF]
, 2013 Genome-wide prediction of transcription factor binding sites is notoriously difficult. We have developed and applied a logistic regression approach for prediction of binding sites for the p53 transcription factor that incorporates sequence information ...
Barker, Daniel +2 more
core +1 more source
p32 is a negative regulator of p53 tetramerization and transactivation
Molecular Oncology, 2019 p53 is a sequence‐specific transcription factor, and proper regulation of p53 transcriptional activity is critical for orchestrating different tumor‐suppressive mechanisms.
Nikhil Baban Ghate +5 more
doaj +1 more source